Amgen has made further inroads into diabetes drug development by licensing a small-molecule glucokinase activator, ARRY-403, from Array BioPharma. The drug, which is in Phase I trials, has demonstrated dose-dependent glucose reduction. Amgen has stumped up US$60 M upfront for exclusive worldwide rights.